-
公开(公告)号：US20180207150A1
公开(公告)日：2018-07-26
申请号：US15933671
申请日：2018-03-23
申请人： The Board of Trustees of the University of Illinois , The Board of Regents of the University of Texas System
发明人： Paul J. HERGENROTHER , David A. BOOTHMAN , Joseph S. BAIR , Rahul PALCHAUDHURI , Elizabeth I. PARKINSON
IPC分类号： A61K31/4745 , A61K45/06
CPC分类号： A61K31/4745 , A61K31/47 , A61K45/06 , C07D471/04 , C07F9/6561 , C07H15/26
摘要： Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.
-
公开(公告)号：US20160030457A1
公开(公告)日：2016-02-04
申请号：US14783344
申请日：2014-04-08
申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS , THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
发明人： Paul J. HERGENROTHER , David A. BOOTHMAN , Joseph S. BAIR , Lifen CAO , Jinming GAO , Xiumei HUANG , Xiuquan LUO , Xinpeng MA , Zachary R. MOORE , Elizabeth I. PARKINSON
IPC分类号： A61K31/706 , A61K31/4745 , A61K45/06 , A61K31/353 , A61K31/131
CPC分类号： A61K31/706 , A61K31/131 , A61K31/353 , A61K31/4738 , A61K31/4745 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , A61K2300/00
摘要： The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
摘要翻译： 本文所述的疗法可以选择性地对受试者中各种不同的癌细胞类型和癌症状况致命。 本文所述的联合治疗可用于治疗，治疗，控制或辅助治疗疾病，其中选择性致死性在化学治疗中是有益的，特别是在疾病伴随着NQO1水平升高的情况下。
-
公开(公告)号：US20180099002A1
公开(公告)日：2018-04-12
申请号：US15834052
申请日：2017-12-06
申请人： The Board of Regents of the University of Texas System , The Board of Trustees of the University of Illinois
发明人： Paul J. HERGENROTHER , David A. BOOTHMAN , Joseph S. BAIR , Lifen CAO , Jinming GAO , Xiumei HUANG , Xiuquan LUO , Xinpeng MA , Zachary R. MOORE , Elizabeth I. PARKINSON
IPC分类号： A61K31/706 , A61K31/4745 , A61K31/4738 , A61K31/131 , A61K45/06 , C12Q1/6886 , A61K31/353
摘要： The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
-
公开(公告)号：US20180057888A1
公开(公告)日：2018-03-01
申请号：US15557608
申请日：2016-03-08
IPC分类号： C12Q1/68 , C12N15/113 , A61N5/10
CPC分类号： C12Q1/6886 , A61N5/10 , C12N15/1137 , C12N2310/14 , C12N2310/531 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , C12Y204/0203 , G01N33/574 , G01N2333/4703 , G01N2800/52 , G01N2800/56
摘要： The present disclosure is directed to methods of detecting KUB5/HERA expression levels, copy number and mutation status, particularly in cancer cells. The methods permit physicians to tailor therapies to subject having certain genotypes/phenotypes, and to exclude therapies unlikely to be effective.
-
公开(公告)号：US20170342503A1
公开(公告)日：2017-11-30
申请号：US15602004
申请日：2017-05-22
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , G01N33/574 , G01N33/57415 , G01N33/57438
摘要： The present disclosure is directed to methods of detecting XRN2 expression levels, copy number and mutation status, particularly in cancer cells. The methods permit physicians to tailor therapies to subject having certain genotypes/phenotypes, and to exclude therapies unlikely to be effective.
-
-
-
-
搜索结果
5 条记录 (耗时 0.051 秒)
